Marcus Schmidt
Overview
Explore the profile of Marcus Schmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
306
Citations
6992
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Linz V, Battista M, Hummel R, Schepers M, Griemert E, Schmidt M, et al.
Oncol Res Treat
. 2025 Feb;
:1-15.
PMID: 39999813
Introduction: Epidural anesthesia is a standard procedure to mitigate pain during surgery for endometrial cancer (EC). Little data exist about the influence of epidural anesthesia on the oncological outcome in...
2.
Schmidt M, Hesse T, Hoffmann O, Heinrich B, Park-Simon T, Grischke E, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941823
Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. The final analysis of the IRENE study assessed the incidence and resolution of eribulin-induced...
3.
Gould E, Fraser H, Parker T, Nakagawa S, Griffith S, Vesk P, et al.
BMC Biol
. 2025 Feb;
23(1):35.
PMID: 39915771
Although variation in effect sizes and predicted values among studies of similar phenomena is inevitable, such variation far exceeds what might be produced by sampling error alone. One possible explanation...
4.
Thomas A, Pohle B, Schmidt M, Bischoff H, Lau M, Heubner F, et al.
ACS Omega
. 2025 Feb;
10(3):2699-2711.
PMID: 39895743
Secondary reactions and solid-electrolyte interface (SEI) formation are crucial aspects for battery lifetime. We show that one part of a natural SEI consists of crystalline NaH, which is formed on...
5.
Ignatiadis M, Bailey A, McArthur H, El-Abed S, de Azambuja E, Metzger O, et al.
JAMA
. 2025 Jan;
PMID: 39883436
Importance: Triple-negative breast cancer is an aggressive subtype with a high incidence in young patients, a high incidence in non-Hispanic Black women, and a high risk of progression to metastatic...
6.
Lopez J, Powles T, Braiteh F, Siu L, LoRusso P, Friedman C, et al.
Nat Med
. 2025 Jan;
31(1):152-164.
PMID: 39762422
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from...
7.
Heimes A, Shehaj I, Almstedt K, Krajnak S, Schwab R, Stewen K, et al.
Int J Mol Sci
. 2024 Oct;
25(20).
PMID: 39456897
Interleukins play dual roles in breast cancer, acting as both promoters and inhibitors of tumorigenesis within the tumor microenvironment, shaped by their inflammatory functions. This study analyzed the subtype-specific prognostic...
8.
Schmidt M, Loibl S
Breast
. 2024 Oct;
78():103821.
PMID: 39405593
The incidence of breast cancer increases with age. Particularly in ageing societies, breast cancer has a significant impact on both the older patient and the healthcare system. In older patients...
9.
Zimmer P, Esser T, Lueftner D, Schuetz F, Baumann F, Rody A, et al.
BMC Med
. 2024 Oct;
22(1):442.
PMID: 39379960
Background: Increased levels of physical activity are associated with a reduction of breast cancer mortality, especially in postmenopausal women with positive hormone receptor status. So far, previous observational case-control and...
10.
Ruckhaberle E, Schmidt M, Welt A, Harbeck N, Wockel A, Gluz O, et al.
Geburtshilfe Frauenheilkd
. 2024 Sep;
84(9):813-836.
PMID: 39229634
Endocrine-based combination therapy with an inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6 inhibitors) is currently the first-line therapy of choice for patients with hormone receptor-positive (HR+) and human...